Page last updated: 2024-09-05

erlotinib and 3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid

erlotinib has been researched along with 3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid in 1 studies

Compound Research Comparison

Studies (erlotinib)	Trials (erlotinib)	Recent Studies (post-2010) (erlotinib)	Studies (3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid)	Trials (3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid)	Recent Studies (post-2010) (3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid)
221	0	180	9	0	8

Protein Interaction Comparison

Protein	Taxonomy	erlotinib (IC50)	3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid (IC50)
Tyrosine-protein phosphatase non-receptor type 11	Homo sapiens (human)		6.0833

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, CH; Chen, YN; Chen, Z; Deng, Z; Fekkes, P; Firestone, B; Fodor, M; Fortin, PD; Fridrich, C; Garcia Fortanet, J; Grunenfelder, D; Ho, S; Kang, ZB; Karki, R; Kato, M; Keen, N; LaBonte, LR; LaMarche, MJ; Larrow, J; Lenoir, F; Liu, G; Liu, S; Lombardo, F; Majumdar, D; Meyer, MJ; Palermo, M; Perez, L; Pu, M; Ramsey, T; Sellers, WR; Shultz, MD; Stams, T; Towler, C; Wang, P; Williams, SL; Zhang, JH	1

Studies

Chen, CH; Chen, YN; Chen, Z; Deng, Z; Fekkes, P; Firestone, B; Fodor, M; Fortin, PD; Fridrich, C; Garcia Fortanet, J; Grunenfelder, D; Ho, S; Kang, ZB; Karki, R; Kato, M; Keen, N; LaBonte, LR; LaMarche, MJ; Larrow, J; Lenoir, F; Liu, G; Liu, S; Lombardo, F; Majumdar, D; Meyer, MJ; Palermo, M; Perez, L; Pu, M; Ramsey, T; Sellers, WR; Shultz, MD; Stams, T; Towler, C; Wang, P; Williams, SL; Zhang, JH

Other Studies

1 other study(ies) available for erlotinib and 3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid

Article	Year
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. Journal of medicinal chemistry, 2016, 09-08, Volume: 59, Issue:17 Topics: Administration, Oral; Allosteric Regulation; Allosteric Site; Animals; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Female; Heterografts; High-Throughput Screening Assays; Humans; Male; Mice, Inbred C57BL; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Piperidines; Protein Conformation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrazines; Pyrimidines; Structure-Activity Relationship	2016

Article

Year

Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.

Journal of medicinal chemistry, 2016, 09-08, Volume: 59, Issue:17

Topics: Administration, Oral; Allosteric Regulation; Allosteric Site; Animals; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Female; Heterografts; High-Throughput Screening Assays; Humans; Male; Mice, Inbred C57BL; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Piperidines; Protein Conformation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrazines; Pyrimidines; Structure-Activity Relationship

2016